A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis

Trial Profile

A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2016

At a glance

  • Drugs Bimekizumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Adverse reactions; Pharmacokinetics; Proof of concept
  • Sponsors UCB
  • Most Recent Events

    • 10 Jun 2016 According to an UCB media release, positive results (n=52) were presented at the Annual European Congress of Rheumatology (EULAR) 2016.
    • 10 Jun 2016 Positive results (n=52) published in an UCB media release.
    • 31 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top